1. Introduction
===============

Myocardial infarction is caused by acute thrombotic occlusion of an epicardial coronary artery and accounts for almost 20% of deaths in Europe in 2015.[@cvy036-B1] A major trigger of arterial thrombosis is endothelial activation or dysfunction, which activates tissue factor (TF), a key initiator of the coagulation cascade. In the context of an acute myocardial infarction, the formation of coagulation factors is enhanced by inflammatory stimuli and reactive oxygen species (ROS) thereby accelerating thrombus formation by increasing platelet activation and aggregation and by inhibiting fibrinolysis.[@cvy036-B2] Furthermore, activated endothelial cells express adhesion molecules that recruit platelets, monocytes, and neutrophils. Interestingly, neutrophils are among the first cells to reach sites of endothelial activation and damage, where they bind to expressed adhesion molecules or exposed subendothelial layers stimulate the expression of TF and thereby initiate coagulation. In line with this concept, inhibiting neutrophil adhesion is associated with reduced amounts of TF.[@cvy036-B3]

Neutrophils exhibit several lines of defence for pathogen elimination in the blood stream, i.e. degranulation, phagocytosis, and formation of neutrophil extracellular traps (NETs), an event where ROS play a key role.[@cvy036-B4] NET formation has been considered a programmed cell death mechanism (Enosis), whereby the intracellular content of neutrophils is externalized in a web-like structure that is able to kill microbes.[@cvy036-B5] This view has recently been challenged by observations that NETs mainly consist of *mitochondrial* DNA and that neutrophils remain viable after releasing NETs. A trigger of NET formation is bacterial endotoxemia, which is derived from the gut microbiome and induces a pro-inflammatory state that is associated with cardiovascular disease (CVD) in humans.[@cvy036-B6] One of the endotoxins that accelerate CVD is lipopolysaccharide (LPS), a component of the bacterial cell membrane. In neutrophils, LPS induces ROS production and enhances NET formation.[@cvy036-B5]^,^[@cvy036-B7] NETs display strong prothrombotic properties as they bind several proteins such as TF that initiate coagulation and promote thrombin generation.[@cvy036-B8]^,^[@cvy036-B9] Indeed, NETs have been associated with the severity of atherosclerosis and thrombosis and have been identified in human coronary thrombi, at lesion sites of ST-elevation myocardial infarction (STEMI).[@cvy036-B10]

Sirtuins comprise a family of seven highly conserved nicotinamide adenine dinucleotide (NAD^+^)-dependent deacetylases and ribosylases with protective effects in aging, apoptosis, inflammation, and oxidative stress.[@cvy036-B11]^,^[@cvy036-B12] Evidence for a putative role of sirtuins in thrombosis is limited to a study of pharmacological *inhibition* of the nuclear sirtuin 1 (*Sirt1*), which augments arterial thrombosis by increasing TF expression and activity through activation of ΝFκΒ,[@cvy036-B13] and an associative study suggesting that inhibition of sirtuin 1, 2 or 3 worsens thrombosis by inducing apoptosis-like changes in platelets.[@cvy036-B14]

Mitochondrial sirtuin 3 (Sirt3) maintains mitochondrial function in low-energy conditions and activates anti-oxidant defence mechanisms.[@cvy036-B15] Sirt3 deacetylases and thus, activates superoxide dismutase 2 (Sod2), the main scavenger of superoxide radicals in mitochondria.[@cvy036-B16] Sirt3 also upregulates expression of Sod2 and catalase, another ROS scavenger in the mitochondria.[@cvy036-B17] Along these lines, a protective role of Sirt3 has been implicated in metabolic, age-, and oxidative stress-related diseases.[@cvy036-B18] Interestingly, *Sirt3*^−/−^ mice exhibit mitochondrial protein hyperacetylation, but remain metabolically normal under basal conditions. Indeed, histological examinations of liver, brown adipose tissue, heart, brain, kidney, and skeletal muscle, mitochondrial numbers, body weight, and fat content, as well as energy balance were not different when comparing *Sirt3*^−/−^ mice to their wild-type (WT) littermates.[@cvy036-B19] However, loss of *Sirt3* in combination with a high-cholesterol diet is sufficient to disturb this equilibrium: Under these conditions, the metabolic derangement increases oxidative stress in endothelial mitochondria and induces mild endothelial dysfunction.[@cvy036-B20] Notably, the role of *Sirt3* in arterial thrombosis remains unknown. Thus, we hypothesized that constitutive *Sirt3* loss-of-function increases oxidative stress in vascular cells, increases procoagulant properties and eventually accelerates arterial thrombus formation.

2. Methods
==========

Primer sequences are available in the supplementary material at *Cardiovascular Research* online.

2.1 Mice
--------

Mice with a germline *Sirt3* deletion were obtained and congenic C57BL6/J *Sirt3*^−/−^ mice were generated through nine generations of backcrosses with C57BL6/J mice.[@cvy036-B21]^,^[@cvy036-B22]*Sirt3^+/+^* WT and *Sirt3*^−/−^ mice were kept in a temperature-controlled facility with a 12-h light/dark cycle and free access to normal chow and water for 16 weeks. All animal experiments were approved by, and carried out in accordance with local veterinary authorities (Veterinary Office of the Canton Zurich, permit numbers: 239/2013 and ZH023/17), as well as the guidelines from Directive 2010/63/EU and institutional guidelines. Mice were administered an intraperitoneal injection of 5 mg/kg LPS (E. coli O111: B4, Sigma--Aldrich) 10 h prior to experiments or organ harvesting, respectively.

2.2 Laser-induced carotid thrombosis *in vivo*
----------------------------------------------

Carotid thrombosis was performed using male WT and *Sirt3*^−/−^ mice. Mice were anaesthetized using 87 mg/kg sodium pentobarbital (Butler). Rose bengal (Fisher Scientific) was injected in the tail vein at a concentration of 63 mg/kg. The right common carotid artery was exposed following a midline cervical incision. A Doppler flow probe (Transonic Systems) was applied and connected to a flowmeter (Transonic, Model T106) and a 1.5mW green laser (540 nm; Melles Griot) was applied to the site of injury at a distance of 6 cm for 60 min. Blood flow was monitored from laser onset for maximum 120 min, or until occlusion (flow ≤0.1 mL for 1 min) occurred.

2.3 NET formation
-----------------

Neutrophils were isolated from mouse bone marrows (BM) using gradient centrifugation.[@cvy036-B23] For each condition, 50 000 cells were plated into one well of a black, clear-bottom 96 well plate (Corning) and incubated for 30 min at 37°C. All wells were then supplied with 5 µM SYTOX Green (ThermoFisher Scientific) and, thereafter, stimulated with 2 µg/mL LPS (E. coli O111: B4, Sigma--Aldrich) or vehicle control. Fluorescence (ex/em = 488/523) was measured every 5 min over 4 h at 37°C in a plate reader (Tecan).

2.4 Human samples
-----------------

Patients with acute coronary syndromes (ACS) were prospectively enrolled between 2009 and 2012 into the multicentre Swiss SPUM-ACS cohort (NCT01000701). Inclusion criteria for this subgroup of patients recruited at the University Hospital Zurich comprised diagnosis of STEMI, age ≥18 years and presentation within 72 h after pain onset. Exclusion criteria were severe physical disability, inability to comprehend study or life expectancy \<1 year for non-cardiac reasons.

Healthy individuals were recruited from the local blood bank and invited for an outpatient visit at University Hospital Zurich. Individuals were eligible if none of the following exclusion criteria were found by history, clinical exam, blood analysis or echocardiogram: Age \<18 years, use of cardiovascular medication, positive cardiovascular family history, smoking (including cessation of smoking within 2 years prior to study enrolment), history of hypertension, elevated total cholesterol (≥5.0 mmol/L), BMI \> 30 kg/m^2^, history of diabetes mellitus, evidence of relevant valvular or structural heart disease and/or a reduced LV ejection fraction (LVEF; \<55%) on echocardiogram.

In STEMI patients, blood was drawn at the beginning of catheterization (after sheath insertion). Leukocytes were separated from whole blood by Ficoll density gradient centrifugation (400× RCF, 30 min at 22°C). Cells were stained for 10 min on ice using human CD14-FITC antibody (Miltenyi Biotec) and subsequently sorted using a FACSAria III 4 L (BD Biosciences). RNA of CD14^+^ cells was isolated and analysed as described in the [Supplemental material online](#sup1){ref-type="supplementary-material"}.

The study complies with the Declaration of Helsinki, and the locally appointed ethics committee approved the research protocol. Informed consent was obtained from all subjects.

2.5 Rotational thromboelastometry
---------------------------------

Whole blood was taken from the mice by right ventricular puncture and decalcified by adding 1/10 (v/v) 3.2% sodium citrate. For plasma analyses, decalcified whole blood was centrifuged for 10 min at 2000×*g* and the resulting plasma supernatant was used. Whole blood was analysed in the rotational thromboelastometry (ROTEM) delta machine according to the manufacturer's instructions using the star-tem, fib-tem, and ex-tem reagents. Plasma was analysed using the ROTEM mini accessories to allow for smaller volumes (equipment and reagents by Tem International GmbH).

2.6 ELISA
---------

Plasma was derived from whole blood as described earlier and was subjected to ELISA for quantifying levels of coagulation factors V, VII, and IX (all ELISAs from Cloud-Clone Corp.), tissue factor (R&D Systems Inc.) and tissue factor activity according to manufacturer's instructions (Sekisui Diagnostics LLC).

2.7 Whole blood platelet aggregometry
-------------------------------------

Whole blood was collected as described earlier. Whole blood was diluted 1:3 in 0.9% saline and aggregometry performed in response to thrombin (2 U/mL, Sigma--Aldrich) at 37°C using impedance aggregometry (Chrono-log Corporation).

2.8 Expression analyses
-----------------------

Liver and aortae samples were homogenized using the Precellys 24 homogenizer (Bertin technologies). Total RNA was isolated from homogenized samples and from isolated human CD14^+^ cells using TRI Reagent (Sigma--Aldrich) according to the manufacturer's instructions and mRNA was translated to cDNA using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare). SYBR^®^ green based real-time quantitative PCR (RT-PCR) was carried out according to standard protocol using a Quant Studio 7 Flex Real Time PCR thermocycler (Applied Biosystems) and expression calculated using the ΔΔ*C*~T~ method normalizing values to expression of GAPDH.

2.9 RT-PCR primers
------------------

Primers sequences were obtained from the qPrimer Depot database (<https://mouseprimerdepot.nci.nih.gov/>; Wenwu Cui PhD, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health). Sequences were synthesized by Microsynth, Switzerland.

2.10 Statistics
---------------

Metric variables were assessed for distribution using the D'Agostino-Pearson omnibus normality test. For *n *\<* *8, non-parametric distribution was assumed. Different groups were compared using unpaired Student's *t* tests for normally distributed data, or Mann--Whitney tests for data with non-parametric distribution. *P* values are two-tailed. Significance was accepted for *P *\<* *0.05. Data are presented as mean ± SD (scatter plots and table) or as mean ± SEM (time-dependent curves). Statistical analyses were performed using Prism 6 for Mac OS X (GraphPad Software).

3. Results
==========

3.1 Loss of *Sirt3* accelerates time to arterial thrombotic occlusion in an inflammatory setting *in vivo*
----------------------------------------------------------------------------------------------------------

To assess the effects of *Sirt3* loss-of-function on thrombosis, time to arterial occlusion was analysed in *Sirt3*^−/−^ and *Sirt3^+/+^* WT mice following laser-induced carotid endothelial injury after lipopolysaccharide (LPS) challenge (*Figure*[*1*](#cvy036-F1){ref-type="fig"}*A--E*). Compared to WT controls, *Sirt3*^−/−^ mice showed a 55% reduction in time to occlusion (*Figure*[*1*](#cvy036-F1){ref-type="fig"}*B*). A representative blood flow tracing of one individual animal of each group shows the reduction of blood flow over the time course of the experiment. The line at 0.1 mL/min indicates the threshold flow regarded as carotid occlusion (*Figure*[*1*](#cvy036-F1){ref-type="fig"}*C*). Initial blood flow and heart rate did not differ between the two groups (*Figure [1](#cvy036-F1){ref-type="fig"}D* and *E*).

![Loss of *Sirt3* accelerates time to carotid thrombotic occlusion *in vivo.* Mouse model of laser-induced carotid thrombosis (*A*): The right carotid artery was dissected and blood flow measured using a Doppler flow probe (FP). A laser (L) pointing at the carotid artery was exciting a previously intravenously injected photo-reactant resulting in endothelial damage and subsequent thrombus formation. Time to thrombotic occlusion in *Sirt3*^−/−^ mice was cut in half compared to WT controls following lipopolysaccharide (LPS) challenge (*B*). The tracing shows mean blood flow until occlusion (mean flow ≤ 0.1 mL for 1 min) (*C*). Initial blood flow and heart rate remained unaltered between the groups (*D* and *E*). *n* ≥ 6, Mann--Whitney test was used for statistical analysis of all graphs.](cvy036f1){#cvy036-F1}

3.2 Loss of *Sirt3* enhances clot formation and increases clot firmness *ex vivo*
---------------------------------------------------------------------------------

The effects of *Sirt3* deficiency on clotting properties of whole blood were investigated using ROTEM (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*A*). Tomograms analyses from WT (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*B*) and *Sirt3*^−/−^ whole blood (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*C*) revealed that *Sirt3*^−/−^ mice displayed an accelerated clotting time (CT, i.e. time to initiation of clotting) (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*D*) and decreased clot formation time (CFT, i.e. time between initiation of clotting and a clot strength of 20 mm amplitude) (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*E*). Clot firmness was increased over the course of the entire experiment in whole blood of *Sirt3*^−/−^ mice compared to WT controls (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*F*). Area under the curve analyses revealed a 30% increase in clot firmness in *Sirt3*^−/−^ mice compared to the control group (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*G*). The maximum clot firmness was increased in the *Sirt3*-deficient group (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*H*), whereas time to maximum clot firmness was decreased in *Sirt3*^−/−^ compared to WT controls (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*I*). These data indicate that *Sirt3*^−/−^ mice exhibit altered blood clotting properties independent of the vessel wall, that cause accelerated thrombotic carotid occlusion *in vivo.*

![Loss of *Sirt3* accelerates blood clotting and clot firmness *ex vivo*. Whole blood coagulation was assessed using rotational thromboelastometry (ROTEM) (*A*). Once the blood started to coagulate, the rotation of the pin was restricted and the kinetics translated to a TEMogram. Representative pictures show the TEMogram from WT (*B*) compared to *Sirt3*^−/−^ whole blood (*C*). *Sirt3*^−/−^ blood revealed an earlier onset of clotting (*D*) and reached a predefined clot firmness earlier than control mice (*E*). Furthermore, blood of *Sirt3*^−/−^ animals showed increased clot firmness throughout the experiment (*F--H*) and maximum clot firmness was reached earlier (*I*). *n* ≥ 6, Student's *t*-test was used in graph (*D*) and (*I*), Mann--Whitney test was applied in graphs (*E*), (*G*), and (*H*). CT, clotting time (time until initiation of clotting); CFT, clot formation time (time between initiation of clotting and a clot strength of 20 mm amplitude).](cvy036f2){#cvy036-F2}

3.3 Transcription levels of thrombosis-associated genes in mouse aortic lysates do not differ between *Sirt3*^−/−^ and WT mice
------------------------------------------------------------------------------------------------------------------------------

To address the involvement of the arterial wall, we assessed transcription of key pro- or anticoagulant genes in mouse aortic lysates. These analyses revealed no difference in transcription levels of *Ft.*, Tf pathway inhibitor (*Tfpi*), von Willebrand factor (*vWf*), plasminogen activator inhibitor 1 (*Pai-1*), *Pai-2*, thrombomodulin (*Thbd*), intercellular adhesion molecule 1 (*Icam-1*), vascular cell adhesion molecule 1 (*Vcam-1*) or tissue plasminogen activator (*tPa*), respectively (see [Supplementary material online, *Figure S1A--I*](#sup1){ref-type="supplementary-material"}).

3.4 Cell and platelet depletion in *Sirt3*^−/−^ blood normalize clot formation time and clot firmness
-----------------------------------------------------------------------------------------------------

To differentiate between the contribution of corpuscular vs. soluble blood components, ROTEM experiments were repeated using platelet-poor plasma (*Figure*[*3*](#cvy036-F3){ref-type="fig"}*A*). The TEMogram of WT plasma (*Figure*[*3*](#cvy036-F3){ref-type="fig"}*B*) vs. *Sirt3*^−/−^ plasma (*Figure*[3](#cvy036-F3){ref-type="fig"}*C*) revealed that the clotting time was decreased in *Sirt3*-deficient plasma (*Figure*[*3*](#cvy036-F3){ref-type="fig"}*D*). Of note, the differences in clot formation time and clot firmness observed in ROTEM experiments using whole blood were abolished in the absence of blood cells and platelets (*Figure*[*3*](#cvy036-F3){ref-type="fig"}*E--I*), suggesting a role of these blood components in *Sirt3*-mediated thrombosis.

![Cell depletion of *Sirt3*^−/−^ blood rescues clot formation time and clot firmness, but not time to initiation of clotting. Murine plasma depleted of all cells was analysed using ROTEM (*A*). Once the factors in the plasma started to coagulate, the rotation of the pin was restricted and the kinetics translated to a TEMogram. Representative pictures show the TEMogram from WT (*B*) compared to *Sirt3*^−/−^ plasma (*C*). Clotting time was reduced in *Sirt3*^−/−^ vs. WT plasma (*D*). No differences could be observed in all other parameters after depleting the blood of cellular components (*E--I*). *n* ≥ 7, Student's *t*-test was used to analyse graphs (*D*) and (*E*) and graphs (*G--I*) were analysed with the Mann--Whitney test. CT, clotting time (time until initiation of clotting); CFT. clot formation time (time between initiation of clotting and a clot strength of 20 mm amplitude).](cvy036f3){#cvy036-F3}

3.5 Platelets do not play a role in *Sirt3*-mediated thrombosis
---------------------------------------------------------------

Platelet counts did not differ between *Sirt3*^−/−^ and WT mice (see [Supplementary material online, *Figure S2A*](#sup1){ref-type="supplementary-material"}), nor did *ex vivo* platelet aggregation after stimulation of whole blood with thrombin (see [Supplementary material online, *Figure S2B and C*](#sup1){ref-type="supplementary-material"}). ROTEM analysis showed that the difference in clotting time was abolished between the two groups after adding exogenous TF and inhibiting platelet aggregation (see [Supplementary material online, *Figure S2D*](#sup1){ref-type="supplementary-material"}), whereas the other differences in clot formation time, clot firmness over time, and maximal clot firmness persisted (see [Supplementary material online, *Figure S2E--H*](#sup1){ref-type="supplementary-material"}). No difference in time to maximum clot firmness was observed (see [Supplementary material online, *Figure S2I*](#sup1){ref-type="supplementary-material"}).

3.6 Exogenous TF accelerates clotting initiation in WT whole blood
------------------------------------------------------------------

ROTEM analysis was performed on whole blood to investigate why the difference in clotting time was lost after inhibition of platelets and addition of exogenous TF (as observed in [Supplementary material online, *Figure S2D*](#sup1){ref-type="supplementary-material"}). Addition of exogenous TF without platelet inhibition abolished the difference in clotting time (see [Supplementary material online, *Figure S3A*](#sup1){ref-type="supplementary-material"}). In contrast, the differences in clot formation time, clot firmness over time, and maximal clot firmness persisted between the two groups (see [Supplementary material online, *Figure S3B--E*](#sup1){ref-type="supplementary-material"}). No difference in time to maximum clot firmness was detected (see [Supplementary material online, *Figure S3F*](#sup1){ref-type="supplementary-material"}).

3.7 Loss of *Sirt3* favours NET formation in mouse neutrophils
--------------------------------------------------------------

After excluding a platelet contribution in *Sirt3*-mediated thrombosis, we focused on neutrophils, as they have been shown to be the first cells recruited at the site of endothelial damage. Neutrophils were isolated from BM and stimulated with LPS. NET formation in *Sirt3*^−/−^ compared to WT neutrophils was increased early on after stimulation and persisted for 4 h (*Figure*[*4*](#cvy036-F4){ref-type="fig"}*A*). Area under the curve analyses revealed a 75% increase in NET formation in *Sirt3*^−/−^ cells over time (*Figure*[*4*](#cvy036-F4){ref-type="fig"}*B*). Representative photomicrographs of unstimulated WT neutrophils, as well as WT and *Sirt3*^−/−^ neutrophils after 2 h of LPS stimulation show no difference in unstimulated vs. stimulated WT cells and a typical net-like externalization of DNA in the *Sirt3*^−/−^ group (*Figure*[*4*](#cvy036-F4){ref-type="fig"}*C*). Fluorescence-activated cell sorting (FACS) analysis for the neutrophil markers Ly6G and CD11b identified 83% of isolated cells as neutrophils (*Figure*[*4*](#cvy036-F4){ref-type="fig"}*D*) and \>97% as viable (*Figure*[*4*](#cvy036-F4){ref-type="fig"}*E*).

![*Sirt3* deficiency favours NET formation in bone marrow-derived mouse neutrophils. NET formation over 4 h was evaluated using SYTOX green nucleic acid stain. *Sirt3*^−/−^ neutrophils (*n*=10) showed increased NET formation upon stimulation with 2 μg/mL LPS when compared to WT neutrophils (*n*=7) (*A*). The difference was quantified analysing the area under the curve using the Mann--Whitney test (AUC, *B*). Representative photomicrographs of unstimulated WT as well as stimulated WT and *Sirt3*^−/−^ neutrophils (visualised as white outlines using light microscopy) illustrate NET formation (stained with SYTOX green) in the Sirt3-deficient group after 2-h stimulation with 2 µg/mL LPS (*C*, bar=50 µm). FACS analyses of cells from a WT mouse showed that isolated cells were 83% granulocytes (*D*) and viable (\>97%; *E*). Ly6G, Lymphocyte antigen 6 complex locus G6D; CD11b, cluster of differentiation molecule 11b; CD45.2, cluster of differentiation molecule 45 expressed by Ly5.2 bearing mouse strains; PI, phosphatidylinositol.](cvy036f4){#cvy036-F4}

3.8 Loss of *Sirt3* increases plasma tissue factor expression and activity
--------------------------------------------------------------------------

To address the difference in clotting time between *Sirt3*^−/−^ and WT controls observed using ROTEM (*Figure*[*2*](#cvy036-F2){ref-type="fig"}*D*), and its rescue upon exogenous TF (see [Supplementary material online, *Figures S2D and S3A*](#sup1){ref-type="supplementary-material"}), plasma was analysed for TF levels and activity. *Sirt3*^−/−^ mice displayed higher levels of soluble TF than WT controls (*Figure*[*5*](#cvy036-F5){ref-type="fig"}*A*). Increased levels of TF translated into increased TF activity in the plasma of *Sirt3*^−/−^ mice compared to WT controls (*Figure*[*5*](#cvy036-F5){ref-type="fig"}*B*). As coagulation factors are predominantly synthesized in the liver, liver lysates were analysed. Expression analyses revealed elevated mRNA levels of the coagulation factors V, VII, and IX in *Sirt3*^−/−^ mice (*Figure*[*5*](#cvy036-F5){ref-type="fig"}*C*). However, these results did not translate into corresponding changes in plasma protein (*Figure*[*5*](#cvy036-F5){ref-type="fig"}*D*).

![Loss of *Sirt3* increases plasma TF levels and activity*. Sirt3*^−/−^ animals showed increased TF levels (*A*, *n* ≥ 6, Mann--Whitney test) and a higher TF activity (*B*, *n* ≥ 9, Student's *t*-test) in plasma than in control animals. Liver mRNAs of locally synthesized coagulation factors V, VII, and IX were elevated in *Sirt3*^−/−^ animals (*C*, *n* = 9, ∗: *P *=* *0.0385 and 0.0402; ∗∗: *P *=* *0.0078, factor VII and XI were analysed using the Mann--Whitney test, the other factors with Student's *t*-test). However, protein plasma levels were not different (*D*, *n* = 8, Factor V analysed by Mann--Whitney test, factors VII and IX by Student's *t*-test).](cvy036f5){#cvy036-F5}

3.9 From mice to men---reduced *Sirt3* and *SOD2* levels in CD14^+^ leukocytes of STEMI patients
------------------------------------------------------------------------------------------------

When comparing BM-derived neutrophils from *Sirt3*^−/−^ and WT mice by real-time quantitative PCR, cells lacking *Sirt3* (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*A*) showed reduced transcription of *Sod2* (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*B*). In humans with acute coronary occlusion and STEMI, PCR analyses of CD14^+^ leukocytes exhibited reduced transcription levels of both *SIRT3* (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*C*) and its downstream target *SOD2* (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*D*) when compared to the respective cell population of healthy donors. However, mouse CD11b^+^ cells lacking *Sirt3* (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*D*) showed no difference in *Sod2* transcription compared to corresponding WT cells (*Figure*[*6*](#cvy036-F6){ref-type="fig"}*E*). Of note, baseline characteristics of STEMI patients and healthy donors did not significantly differ for age, gender, BMI, systolic blood pressure, LDL-cholesterol, and diabetes mellitus---parameters potentially relevant for Sirt3 (*Table*[*1*](#cvy036-T1){ref-type="table"}). Increased stress-induced levels of glucose, C-reactive protein (CRP), and diastolic blood pressure are to be expected in the acute setting of STEMI as compared to the quiescent context of healthy donors.

###### 

Baseline characteristics of healthy donors and STEMI patients

                                    Healthy     STEMI        *P* value
  --------------------------------- ----------- ------------ ---------------------------------------------
  *n*                               10          10           
  Gender (f/m)                      4/6         2/8          0.63[^a^](#tblfn2){ref-type="table-fn"}
  Age (years)                       58±8        62±9         0.39[^b^](#tblfn3){ref-type="table-fn"}
  BMI (kg/m^2^)                     24.0±3.1    26.1±3.3     0.13[^b^](#tblfn3){ref-type="table-fn"}
  Time to catheterization (h)       --          6.76±9.3     --
  Systolic blood pressure (mmHg)    119.1±9.0   123.2±29.3   0.84[^a^](#tblfn2){ref-type="table-fn"}
  Diastolic blood pressure (mmHg)   71.0±8.8    82.3±16.3    0.046[^a^](#tblfn2){ref-type="table-fn"}
  Diabetes history (f/m)            0/0         0/0          --
  Fasting glucose (mmol/L)          5.1±0.6     7.3±1.2      \<0.0001[^a^](#tblfn2){ref-type="table-fn"}
  Total cholesterol (mmol/L)        5.3±0.8     5.5±1.6      0.75[^b^](#tblfn3){ref-type="table-fn"}
  HDL (mmol/L)                      1.7±0.5     1.3±0.3      0.017[^b^](#tblfn3){ref-type="table-fn"}
  LDL (mmol/L)                      3.2±0.6     3.5±1.3      0.47[^b^](#tblfn3){ref-type="table-fn"}
  Triglycerides (mmol/L)            1.0±0.4     0.9±0.4      0.57[^b^](#tblfn3){ref-type="table-fn"}
  CRP (mg/L)                        1.3±1.5     11.3±10.5    0.064[^a^](#tblfn2){ref-type="table-fn"}
  Creatinine (µmol/L)               87.3±10.7   83.3±14.3    0.49[^b^](#tblfn3){ref-type="table-fn"}
  Statins (f/m)                     0/0         1/3          --
  Aspirin (f/m)                     0/0         1/2          --

m/f, number of males/females; BMI, body mass index; time to catheterization, time between pain onset and sheath insertion in the catheterization laboratory; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein. *n* = 10.

Mann--Whitney test.

Student's *t*-test.

![*Sod2* transcription is reduced in *Sirt3-*deficient mouse neutrophils, but not in monocytes---CD14^+^ leukocytes of STEMI patients show reduced *SIRT3* and *SOD2* transcript levels. Murine *Sirt3*^−/−^ neutrophils lack *Sirt3* (*A*) and show reduced transcription of *Sod2* (*B*, *n* ≥ 8, Student's *t*-test). STEMI patients demonstrate reduced mRNA levels of *SIRT3* (*C*) and *SOD2* (*D*) in CD14^+^ cells compared to healthy donors (*n* = 10, both Student's *t*-test). CD11b^+^ cells from *Sirt3*-deficient mice show no differential transcription of *Sod2* compared to WT (*E* and *F*, *n* = 6, Mann--Whitney test).](cvy036f6){#cvy036-F6}

![Scheme illustrating prothrombotic effects of *Sirt3* deficiency. Upon pro-inflammatory stimuli such as bacterial endotoxins (e.g. LPS) or oxLDL known to trigger human atherothrombotic events, endogenous *Sirt3* protects neutrophils from NET formation (left). In contrast, absence of *Sirt3* favours NETs, thereby accelerating clotting and increasing clot firmness (right) in mice. In patients with STEMI, *SIRT3* transcription levels are reduced.](cvy036f7){#cvy036-F7}

4. Discussion
=============

We here show that genetic loss of *Sirt3* in mice accelerates carotid artery occlusion *in vivo* under pro-inflammatory conditions. *Ex vivo* ROTEM revealed accelerated clot initiation, clot formation, and increased clot stability in *Sirt3*-deficient mice. These events were associated with enhanced formation of thrombogenic NETs, increased expression, and activity of TF in plasma and reduced *Sod2* transcription in neutrophils. In CD14^+^ leukocytes isolated from STEMI patients with an acute coronary occlusion, transcription levels of *SIRT3*, and its downstream target *SOD2* were reduced compared to healthy donors.

In the context of thrombosis, formation of NETs is detrimental because of their pro-coagulant properties. NETs bind von Willebrand factor, fibronectin, and fibrinogen, contain inhibitors of the anticoagulant TFPI, provide a large surface for TF and active coagulation factor XII, and promote thrombin generation.[@cvy036-B8]^,^[@cvy036-B9]^,^[@cvy036-B24] These properties provide a scaffold for the binding of platelets and coagulation factors. They also comprise stimuli for platelet aggregation and activating the coagulation cascade. Eventually, these events accelerate clot formation and enhance clot stability, as observed in our *ex vivo* model.

NET formation can be triggered by ROS and a recent study has demonstrated that mitochondrial ROS are sufficient to generate NETs.[@cvy036-B4]*Sirt3* activates transcription of *Sod2*, thereby scavenging mitochondrial ROS. Our findings support the association between mitochondrial ROS and NET formation by showing that loss of *Sirt3* decreases *Sod2* transcription and increases NET formation. The causal role of *Sirt3* in protecting neutrophils from oxidative stress-induced NET formation in animal models of arterial thrombosis supports earlier findings in healthy humans where *SIRT3* was upregulated after intense exercise, to protect against neutrophil-mediated oxidative stress.[@cvy036-B25]

The more rapid onset of clotting in our *Sirt3*^−/−^*ex vivo* model using whole blood could not be reversed after depleting whole blood of its cellular components and platelets. Yet, we found increased amounts of active soluble TF in the plasma as a potential mediator. TF and neutrophils play indeed a major role in arterial thrombosis as both TF plasma levels and neutrophil counts are elevated in ACS patients.[@cvy036-B26] Using a mouse model of laser-induced thrombosis, another group showed that TF is expressed by neutrophils and is present in the blood at the site of injury immediately after laser onset. Upon neutrophil depletion, the amount of TF in the blood at the site of injury was decreased.[@cvy036-B3] Likewise, TF is associated with and expressed in NETs.[@cvy036-B8]^,^[@cvy036-B24] These findings suggest that TF bound to NETs is the reason for increased amounts of active soluble TF in the plasma.

Taking into account our findings and the detrimental role of NETs in ischemia-reperfusion injury,[@cvy036-B27] increased NET formation may explain recent observations in mice, where *Sirt3* deletion impaired left ventricular recovery after myocardial ischaemia.[@cvy036-B28]

Lastly, we found decreased transcript levels of *SIRT3* and *SOD2* in CD14^+^ cells of STEMI patients with acute coronary occlusion, while we observed reduced transcription of *Sod2* in neutrophils of *Sirt3*-deficient mice. Previously, a role for *Sirt3* in transcriptional regulation of *Sod2* had only been described in cardiomyocytes via *FoxO3*.[@cvy036-B17]

4.1 Limitations
---------------

Since loss of *Sirt3* without an additional stressor does not lead to a phenotype, we challenged mice with LPS to mimic a pro-inflammatory state as it occurs in patients with ACS.[@cvy036-B29] Even though some triggers of acute arterial thrombosis may have an infectious source such as acute respiratory infections with influenza,[@cvy036-B30] CVD may develop as a non-infectious chronic inflammatory disease.[@cvy036-B31] Moreover, recent studies suggest that the gut microbiome enhances CVD and neutrophil pro-inflammatory activity[@cvy036-B6]^,^[@cvy036-B32] and impairs outcome in patients with ACS.[@cvy036-B33]

Due to a lack of availability of human neutrophil samples, we used human CD14^+^ leukocytes. With both neutrophils and monocytes being leukocyte subsets, we postulated that a differential expression of *SIRT3* in human monocytes may parallel a differential expression in murine neutrophils. Furthermore, we isolated mouse CD11b^+^ cells, the mouse equivalent to human CD14^+^ cells. Since we could not replicate the changes seen in human CD14^+^ in murine CD11b^+^ cells, our data suggest that an extrapolation between mouse and human leukocytes has to be done with caution. Our findings also suggest that *SOD2* in human neutrophils may not fully account for *SIRT3*-mediated NET formation. A possible reason for the changes in monocytic *SIRT3* expression in humans may lie in the fact that STEMI patients usually suffer from inflammation and atherosclerosis for years before myocardial infarction. Thus, downregulation of *SIRT3* in this case may be a reaction to this chronic condition, which was not replicated in mice apart from exposing them acutely with LPS.

Along the same line, our mouse expertiments highlight a proof-of-principle and *causality* between *Sirt3* deficiency and the thrombosis phenotype in a non-atherosclerotic carotid artery. In humans, context and protagonist cells are different---and we describe an *association* between decreased *SIRT3* in monocytes of STEMI patients. We did not address NETosis and *SIRT3* in humans, yet increased tissue factor and NETosis have been reported in culprit coronary arteries of patients with acute myocardial infarction.[@cvy036-B8] Nevertheless, a *Sirt3*-mediated effect on murine NET formation does exist and our data do not exclude an effect of Sirt3-deficiency on human neutrophils. To test the translatability, our findings have to be replicated in neutrophils from human STEMI patients.

Even though increased TF in plasma may be mainly derived from activated neutrophils, monocytes may contribute, as they have been described to release TF microvesicles.[@cvy036-B34] It is conceivable that the initial release of TF originates from neutrophils, as they are the first cells to reach the site of injury.[@cvy036-B3] Subsequent release of TF from monocytes is likely to be triggered by interactions between neutrophils and the endothelium. Notably, since the discovery of NETs, other types of leukocytes were also shown to release extracellular mitochondrial DNA traps.[@cvy036-B35]^,^[@cvy036-B36] It is possible that these leukocytes contribute to the effects observed *in vivo* and *ex vivo*.

4.2 Conclusions and perspectives
--------------------------------

Our study highlights a protective role of *Sirt3* in neutrophils in a mouse model of acute carotid thrombosis under inflammatory conditions. In line with these findings, acute coronary thrombosis in STEMI patients is associated with decreased protective factors such as lower *SIRT3* and *SOD2* levels in CD14^+^ cells. Future studies in neutrophils of patients with myocardial infarction should be done to more specifically address the association between neutrophil-derived SIRT3, SOD2 levels, and NET formation.

Based on our results, we postulate that activation of *SIRT3* in ACS may improve outcome of STEMI patients by reducing NET-dependent procoagulatory properties. As NETs are described in a variety of other non-infectious diseases,[@cvy036-B37]*SIRT3* activation may also provide beneficial effects in these disease contexts. Indeed, the therapeutic potential of specific sirtuin activators in CVD has been reported.[@cvy036-B18] However, to date no clinically effective specific activator of any of the seven sirtuins has been identified. Investing in the discovery of new substances that can specifically activate certain sirtuins could open new therapeutic possibilities for CVD, as well as other metabolic and age-related diseases. Promising alternative approaches could be to boost SIRT3 expression by transcriptional activation or to use CRISPR technology. Finally, since beneficial roles in CVD have been described also for other sirtuins,[@cvy036-B18] pan-sirtuin activators appear worthy for clinical testing. Recently, the first pilot study using the NAD^+^ precursor nicotinamide riboside (NR) has been completed[@cvy036-B38] and on-going clinical studies are investigating the effect of NR on aging, obesity, insulin resistance, and coronary artery disease.

Supplementary material
======================

[Supplementary material](#sup1){ref-type="supplementary-material"} is available at *Cardiovascular Research* online.

Supplementary Material
======================

###### 

Click here for additional data file.

**Time for primary review: 24 days**

We thank the catheter team and study nurse Anika Adam at the University Heart Center in Zurich for recruiting patients and healthy donors, and Aliki Buhayer (PRISM Scientific Sàrl) for her support in medical writing. *Figure*[*7*](#cvy036-F7){ref-type="fig"} was designed using Servier Medical Art by Servier under a Creative Commons Attribution 3.0 Unported License.

**Conflict of interest:** C.M.M. received research grants from Swiss National Science Foundation, from the University Research Priority Program Integrative Human Physiology at the University of Zurich, and from Hartmann-Müller Foundation during the conduct of the study, as well as grants from MSD, Bayer, AstraZeneca, EliLilly, and speaker fees from MSD, AstraZeneca, Roche, Sanofi, and Amgen outside the submitted work. T.F.L. received grants to the institution from Amgen, AstraZeneca, Bayer Healthcare, Biosensors, Biotronik, Boston Scientific, Eli Lilly, Medtronic, MSD, Merck, Roche and Servier, including speaker fees by some of them. S.W. received grants from Biotronik, Bacco Pharmaceutical, Edwards Lifesciences, Medtronic, and Terumo Inc, as well as grants and speaker fees from Boston Scientific and Daiichi Sankyo, all outside the submitted work. J.A. is a founder and scientific advisory board member of Mitobridge.

Funding
=======

This work was supported by the Swiss National Science Foundation \[31003 A-140780 to J.A., 310030-135815 to T.F.L., 310030-146923 to C.M.M., 310030-165990 to C.M.M. and J.A., 32473B-163271 to F.M., 33CM30-140336 to SPUM-ACS\]; the National Institute of Health (USA) \[R01AG043930 to J.A.\]; the University Research Priority Program Integrative Human Physiology at the University of Zurich to \[C.M.M. and D.S.G.\]; the Hartmann-Müller Foundation to \[C.M.M. and L.J.v.T.\]; the Ecole Polytechnique Fédérale de Lausanne to \[J.A.\]; the University of Zurich to \[C.M.M. and S.W.\]; the Swiss Heart Foundation (to C.M.M); and the Foundation for Cardiovascular Research, Zurich, Switzerland.

[^1]: Stephan Winnik and Christian M. Matter authors contributed equally to the study.
